溶瘤病毒
医学
黑色素瘤
转移性黑色素瘤
食品药品监督管理局
免疫疗法
免疫系统
癌症研究
药品
药物开发
肿瘤科
内科学
药理学
免疫学
作者
Alexandra M. Haugh,Adil Daud
出处
期刊:The cancer journal
[Ovid Technologies (Wolters Kluwer)]
日期:2024-03-01
卷期号:30 (2): 108-112
被引量:1
标识
DOI:10.1097/ppo.0000000000000709
摘要
Abstract Intratumoral therapies represent a unique avenue for drug development in melanoma as patients often have accessible lesions that are particularly amenable to these approaches. In addition, a majority of intratumoral therapies have focused on stimulating antitumor immune responses, making them a particularly attractive option for use in melanoma. In this review, we describe applications for talimogene laherparepvec, a US Food and Drug Administration–approved intratumoral therapy in melanoma, as well as several classes of intratumoral therapies in development including novel oncolytic viruses, mRNA-based intratumoral injections, and cytokines and other signaling molecules.
科研通智能强力驱动
Strongly Powered by AbleSci AI